WallStSmart

Edwards Lifesciences Corp (EW)vsNewmont Goldcorp Corp (NEM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Newmont Goldcorp Corp generates 296% more annual revenue ($24.97B vs $6.30B). NEM leads profitability with a 33.9% profit margin vs 17.4%. EW appears more attractively valued with a PEG of 2.04. NEM earns a higher WallStSmart Score of 78/100 (B+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9

NEM

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 9.5Value: 4.0Quality: 8.0
Piotroski: 6/9Altman Z: 2.04
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued
NEMSignificantly Overvalued (-81.0%)

Margin of Safety

-81.0%

Fair Value

$68.86

Current Price

$116.51

$47.65 premium

UndervaluedFair: $68.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

NEM6 strengths · Avg: 9.8/10
Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
61.4%10/10

Strong operational efficiency at 61.4%

Revenue GrowthGrowth
45.8%10/10

Revenue surging 45.8% year-over-year

EPS GrowthGrowth
78.6%10/10

Earnings expanding 78.6% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$124.38B9/10

Large-cap with strong market position

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

NEM1 concerns · Avg: 2.0/10
PEG RatioValuation
2.782/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : NEM

The strongest argument for NEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 33.9% and operating margin at 61.4%. Revenue growth of 45.8% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Bear Case : NEM

The primary concerns for NEM are PEG Ratio.

Key Dynamics to Monitor

EW carries more volatility with a beta of 0.87 — expect wider price swings.

NEM is growing revenue faster at 45.8% — sustainability is the question.

NEM generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NEM scores higher overall (78/100 vs 61/100), backed by strong 33.9% margins and 45.8% revenue growth. EW offers better value entry with a 69.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Newmont Goldcorp Corp

BASIC MATERIALS · GOLD · USA

Newmont Corporation, based in Greenwood Village, Colorado, United States, is one of the largest gold mining companies in the world.

Visit Website →

Want to dig deeper into these stocks?